Headquarters: Netherlands
Founded: 2012
proqr.com
ProQR Therapeutics confirms QRX-421 was granted orphan drug designation by the FDA and EMA
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA). It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010 and QR-110. It is focusing on developing QRX- 911, QRX- 021, QRX- 313, QRX- 704, QRX- 812, QRX- 411, QRX- 504, QRX- 604 and QRX- 203. QR-010 is an RNA-based oligonucleotide. QR-110, is an oligonucleotide.
Key stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | -4287.92% | -2139.11% |
| Operating margin | -3841.13% | -2164.82% |
| EBITD margin | - | -2096.72% |
| Return on average assets | -85.58% | -47.21% |
| Return on average equity | -110.46% | -54.71% |
| Employees | 133 |
No comments:
Post a Comment